<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476901</url>
  </required_header>
  <id_info>
    <org_study_id>20200566</org_study_id>
    <secondary_id>CDMRP-PR191597</secondary_id>
    <secondary_id>20-02-134</secondary_id>
    <nct_id>NCT04476901</nct_id>
  </id_info>
  <brief_title>Transendocardial Injection of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy</brief_title>
  <acronym>DCMII</acronym>
  <official_title>A Phase IIB Randomized, Placebo-Controlled, Multicenter Study of the Comparative Efficacy and Safety of Transendocardial Injection of Allogeneic-MSC Versus Placebo in Patients With Non- Ischemic Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua M Hare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of an experimental drug
      called human allogeneic mesenchymal stem cell therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LVEF</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in global ventricular strain</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in global ventricular strain as assessed via cardiac Harmonic Phase (HARP) MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left regional strain</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in regional ventricular strain as assessed via cardiac HARP MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function concordance</measure>
    <time_frame>12 months</time_frame>
    <description>The left ventricular function concordance will be measured as the Number of individuals who experienced an increase in left ventricular ejection fraction (LVEF) and a simultaneous decrease in both left ventricular end systolic volume index (LVESVI) and left ventricular end diastolic volume index (LVEDVI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVEDVI</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in left ventricular end diastolic index (LVEDVI) as assessed via cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVESVI</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in left ventricular end systolic index (LVESVI) as assessed via cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maximal oxygen consumption (VO2 max)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in maximal oxygen consumption (VO2max) as assessed via treadmill</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Exercise tolerance</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in exercise tolerance as assessed as the distance covered via the six-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-item questionnaire with a total score ranging from 0 to 105 with lower scores indicative of better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) Class</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>NYHA Classifications of heart failure are as follows: Class I (no limitations); Class II (mild symptoms); Class III (marked limitations); Class IV (Severe limitations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in flow mediated diameter</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in endothelial function will be reported as the percent change in flow mediated diameter assessed via flow mediated dilation (FMD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EPC-CFU</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in NT-proBNP as assessed via blooddraw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE</measure>
    <time_frame>12 months</time_frame>
    <description>Safety will be reported as the incidence of Major Adverse Cardiac Events (MACE) assessed by treating physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TE-SAEs</measure>
    <time_frame>Day 30</time_frame>
    <description>Safety will be reported as the incidence of Treatment Emergent Serious Adverse Events (TE-SAEs) assessed by treating physician</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Non-ischemic Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Genotype A administered with placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants whose blood genotyping resulted with Genotype A (absence of pathogenic mutation) and randomized to the placebo group will receive the placebo intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype A administered with hMSC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants whose blood genotyping resulted with Genotype A (absence of pathogenic mutation) and randomized to the treatment group will receive the hMSC intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype B administered with placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants whose blood genotyping resulted with Genotype B (variance of uncertain determinance) and randomized to the placebo group will receive the placebo intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype B administered with hMSC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants whose blood genotyping resulted with Genotype B (variance of uncertain determinance) and randomized to the treatment group will receive the hMSC intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype C administered with placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants whose blood genotyping resulted with Genotype C (pathogenic variance) and randomized to the placebo group will receive the placebo intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype C administered with hMSC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants whose blood genotyping resulted with Genotype C (pathogenic variance) and randomized to the treatment group will receive the hMSC intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic human mesenchymal stem cells (hMSCs)</intervention_name>
    <description>allo-hMSCs, 20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 100 million allo-hMSCs</description>
    <arm_group_label>Genotype A administered with hMSC Group</arm_group_label>
    <arm_group_label>Genotype B administered with hMSC Group</arm_group_label>
    <arm_group_label>Genotype C administered with hMSC Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as injections of plasmalyte A supplemented with 1% human serum albumin (HSA). 0.5 ml/ injection x 10 injections</description>
    <arm_group_label>Genotype A administered with placebo Group</arm_group_label>
    <arm_group_label>Genotype B administered with placebo Group</arm_group_label>
    <arm_group_label>Genotype C administered with placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In order to be eligible to participate in this study, an individual must meet all of the
        following criteria:

          1. Men and women aged 18 to 80 years at the time of signing the informed consent form.

          2. Diagnosis of NIDCM with left ventricular ejection fraction ≤40%. Note: a left
             ventricular end diastolic diameter (LVEDD) &gt; 5.9cm in male subjects, an LVEDD of &gt;
             5.6cm in female subjects, or left ventricular end diastolic volume index &gt; 125 mL/m2
             (in either sex).

          3. Appropriate guideline-directed optimal medical therapy for non-ischemic
             cardiomyopathy. At a minimum, subjects must be on beta blockers and
             angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)
             or Angiotensin Receptor Neprilysin Inhibitors (ARNI) or have appropriate medical
             indication precluding use of one or both of these agents. Subjects must be on a stable
             regimen for at least 30 days prior to the procedure. Dose titration is allowed.

          4. Be a candidate for cardiac catheterization.

          5. Be willing to undergo DNA test.

        Exclusion Criteria:

        An individual who meets any of the following criteria will be excluded from participation
        in this study:

          1. Be eligible for or require standard-of-care surgical or percutaneous intervention for
             the treatment of non-ischemic dilated cardiomyopathy.

          2. History of Coronary Artery Disease (CAD) or evidence of endocardial or transmural scar
             on cardiac MRI suggestive of undiagnosed CAD. Previous treatment for post-infarction
             left ventricular dysfunction including Percutaneous Coronary Intervention (PCI) and
             thrombolytic therapy. Be indicated for or require coronary artery revascularization.

          3. Documented presence of epicardial stenosis of 70% or greater in one or more major
             epicardial coronary arteries.

          4. Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2)
             severe valvular (any valve) insufficiency/regurgitation within 12 months of consent

          5. Aortic stenosis with valve area ≤ 1.5cm2

          6. Cardiomyopathy due to acute Post-partum (within 6 months), Non-compaction, or
             Hypertrophic cardiomyopathy.

          7. Evidence of a life-threatening arrhythmia in the absence of a defibrillator
             (non-sustained ventricular tachycardia ≥ 20 consecutive beats or complete second or
             third-degree heart block in the absence of a functioning pacemaker) within 30 days of
             consent or the measure of the time interval between the start of the Q wave and the
             end of the T wave in the heart's electrical cycle (QTc) interval &gt; 550 ms on baseline
             electrocardiogram (ECG).

          8. Automated Implantable Cardioverter Defibrillator (AICD) appropriate firing or anti
             tachycardia pacing for ventricular fibrillation within 30 days prior to consent.

          9. Have an estimated baseline glomerular filtration rate &lt;35 ml/min/1.73m2

         10. A hematologic abnormality during baseline testing as evidenced by hemoglobin &lt; 9 g/dl;
             hematocrit &lt; 30%; absolute neutrophil count &lt; 2,000 or total WBC count more than 2
             times upper limit of normal; or platelet values &lt; 100,000/ul

         11. Have liver dysfunction, as evidenced by enzymes Aspartate Transaminase Enzyme (AST)
             and Alanine Aminotransferase Enzyme (ALT) greater than three times the ULN.

         12. Have a bleeding diathesis or coagulopathy (International Normalised Ratio (INR) &gt;
             1.5), cannot be withdrawn from anticoagulation therapy, or will refuse blood
             transfusions.

         13. Be a solid organ transplant recipient. This does not include prior cell based therapy
             (&gt;12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting.

         14. Have a history of organ or cell transplant rejection.

         15. Have a clinical history of malignancy within the past 2 years (i.e., subjects with
             prior malignancy must be disease free for 2 years), except curatively treated basal
             cell or squamous cell carcinoma or cervical carcinoma.

         16. History of drug abuse (illegal &quot;street&quot; drugs except marijuana, or prescription
             medications not being used appropriately for a pre-existing medical condition) or
             alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or
             legal problems arising from the use of alcohol or drugs within the past 24 months.

         17. Be serum positive for HIV, hepatitis B surface antigen, or viremic hepatitis C.

         18. Documented presence of a known Left Ventricular (LV) thrombus, aortic dissection, or
             aortic aneurysm. (Refer to &quot;Guidance to the PI&quot; section with regards to LV thrombus,
             below).

         19. Blood glucose levels (HbA1c) &gt;10%

         20. Severe radiographic contrast allergy.

         21. Hypersensitivity to dimethyl sulfoxide (DMSO).

         22. Non-cardiac condition with life expectancy &lt; 1 year.

         23. Acute stroke or transient ischemic attack within 3 months of enrollment.

         24. Be pregnant, nursing, or of childbearing potential while not practicing effective
             contraceptive methods.

         25. Pacemaker-dependence with an Implantable Cardioverter Defibrillator (ICD) (Note:
             pacemaker-dependent candidates without an ICD are not excluded)

         26. Presence of a pacemaker and/or ICD generator with any of the following
             limitations/conditions:

               -  manufactured before the year 2000

               -  leads implanted &lt; 6 weeks prior to consent

               -  non-transvenous epicardial or abandoned leads

               -  subcutaneous ICDs

               -  leadless pacemakers

         27. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to
             consent

         28. Other MRI contraindications (e.g. subject body habitus incompatible with MRI)

         29. Need for advanced heart failure therapy (e.g. IV inotropes)

         30. Any other condition that in the judgment of the Investigator would be a
             contraindication to enrollment or follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Hare, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelly L Sayre, MPH</last_name>
    <phone>713-500-9529</phone>
    <email>Shelly.L.Sayre@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvenie Desire</last_name>
    <phone>305-243-7273</phone>
    <email>ydesire@miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Fouzia Khan</last_name>
      <phone>650-736-1410</phone>
      <email>fouziak@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Phil Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lina Caceres</last_name>
      <phone>305-243-5399</phone>
      <email>lvc25@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jairo Tovar</last_name>
      <phone>305-243-5399</phone>
      <email>jat243@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Josh Hare, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Heidi Wilson</last_name>
      <phone>502-540-3721</phone>
      <email>heidi.wilson@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Roberto Bolli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>James Chen</last_name>
      <phone>832-355-9366</phone>
      <email>jchen@texasheart.org</email>
    </contact>
    <investigator>
      <last_name>Emerson Perin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cctrn.org</url>
    <description>Cardiovascular Cell Therapy Research Network</description>
  </link>
  <link>
    <url>https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/stem-cells</url>
    <description>Information on stem cells from the National Institutes of Health</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Joshua M Hare</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Allogeneic mesenchymal stem cells</keyword>
  <keyword>Bone marrow-derived mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

